{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:04:09Z","timestamp":1784178249135,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ublituximab is a glycoengineered monoclonal antibody that effectively reduces multiple sclerosis (MS) relapses but carries a significant risk of infusion-related reactions (IRRs), which is relatively higher than that reported for some other anti-CD20 agents. This study aims to characterize real-world IRRs associated with ublituximab and describe premedication practices across participating centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter retrospective study included ublituximab-treated MS patients identified from existing medical records (a convenience sample) at MS centers across the United States. Data on demographics, MS phenotype, premedication regimens, and IRRs were collected. Variables were summarized, and Fisher\u2019s exact test was used to compare the occurrence and timing of IRRs across baseline and premedication categories. Also, associations between premedication strategies and IRRs were assessed by logistic regression. We conducted statistical analyses using JAMOVI (v2.5).\n                      <jats:italic>p<\/jats:italic>\n                      -values were adjusted for multiple comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 89 patients with multiple sclerosis (PwMS) treated with ublituximab, 34.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f31) experienced IRRs. All patients received premedication, with the acetaminophen dose being the only component significantly associated with overall IRR occurrence (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006). Significant differences in reaction timing (immediate versus delayed) were observed across certain corticosteroid and antihistamine categories. All IRRs were mild to moderate in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately one-third (34.8%) of ublituximab-treated patients experienced IRRs, with varied timing and symptom patterns. No independent predictors of IRRs were identified. Importantly, all IRRs observed in this study were mild to moderate, suggesting that ublituximab infusions were generally well tolerated in this real-world cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1840196","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:20:38Z","timestamp":1784175638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Anas Z.","family":"Nourelden","sequence":"first","affiliation":[{"name":"Department of Neurology, Wayne State University, School of Medicine","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker R.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical College of Wisconsin","place":["Milwaukee, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam I.","family":"Hooshmand","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical College of Wisconsin","place":["Milwaukee, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Mazur","sequence":"additional","affiliation":[{"name":"John D. Dingell VA Medical Center","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Mada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Detroit Medical Center","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesiley","family":"Ash","sequence":"additional","affiliation":[{"name":"John D. Dingell VA Medical Center","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wayne State University, School of Medicine","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Rube","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wayne State University, School of Medicine","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Yarraguntla","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wayne State University, School of Medicine","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Deluca","sequence":"additional","affiliation":[{"name":"Washington VA Medical Center","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Yager-Stone","sequence":"additional","affiliation":[{"name":"Portland VA Medical Center","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Havens","sequence":"additional","affiliation":[{"name":"John D. Dingell VA Medical Center","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Wallin","sequence":"additional","affiliation":[{"name":"Washington VA Medical Center","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anza B.","family":"Memon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wayne State University, School of Medicine","place":["Detroit, MI, United States"]},{"name":"John D. Dingell VA Medical Center","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2024","journal-title":"Aktual Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1756285612474333","article-title":"Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges","volume":"6","author":"Lehmann-Horn","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"a029108","DOI":"10.1101\/cshperspect.a029108","article-title":"The multiple roles of B cells in multiple sclerosis and their implications in multiple sclerosis therapies","volume":"9","author":"Li","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.2147\/DDDT.S388410","article-title":"Evaluating the therapeutic potential of Ublituximab in the treatment of MS: design, development and place in therapy","volume":"18","author":"Martin","year":"2024","journal-title":"Drug Design Development Therapy"},{"key":"ref6","article-title":"BRIUMVI\u2122 (ublituximab-xiiy) [prescribing information]","year":"2022"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/nejmoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1473284","DOI":"10.3389\/fneur.2024.1473284","article-title":"Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis","volume":"15","author":"Alvarez","year":"2024","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of anti-Cd20 therapies for multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.17925\/usn.2022.18.2.117","article-title":"Ublituximab: a novel anti-Cd20 therapy for multiple sclerosis","volume":"18","author":"Wolf","year":"2022","journal-title":"US Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-Cd20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2020","journal-title":"Mult Scler J"},{"key":"ref12","article-title":"Infusion-related reactions to monoclonal antibodies for cancer therapy","author":"LaCasce","year":""},{"key":"ref13","first-page":"784","volume-title":"Common Terminology Criteria for Adverse Events","author":"Shah","year":"2022"},{"key":"ref14","year":"2025"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4274\/jmsr.galenos.2023.2022-12-2","article-title":"Real-world results of ocrelizumab in the treatment of multiple sclerosis: a gulf region single-center experience","volume":"3","author":"Hassan","year":"2023","journal-title":"J Mult Scler Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"ref19","article-title":"Glucocorticoid Therapy and Adrenal Suppression. [Updated 2018 Oct 15]","volume-title":"Endotext [Internet]","author":"Nicolaides","year":""},{"key":"ref20","first-page":"5","article-title":"Association between the Incidence of infusion-Related Reactions by Obinutuzumab and the dose of Corticosteroid as Premedication: a Multicenter Retrospective cohort Study","volume-title":"J Pharm Health Care Sci.","author":"Ohtsubo","year":"2026"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/medicina60040659","article-title":"Comparing the risk of infusion-related reactions and tolerability in patients given cetirizine or diphenhydramine prior to ocrelizumab infusion (PRECEPT)","volume":"60","author":"Smoot","year":"2024","journal-title":"Medicina"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.6004\/jadpro.2024.15.2.5","article-title":"Intravenous cetirizine premedication to mitigate infusion-related reactions","volume":"15","author":"Tyler","year":"2024","journal-title":"J Adv Pract Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7224\/1537-2073.2014-030","article-title":"Prevention and Management of Infusion-Associated Reactions in the comparison of alemtuzumab and Rebif\u00ae efficacy in multiple sclerosis (CARE-MS) program","volume":"17","author":"Caon","year":"2015","journal-title":"International J MS Care"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","article-title":"The evolution of anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function","volume":"39","author":"Cree","year":"2025","journal-title":"CNS Drugs"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4161\/mabs.20577","article-title":"Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314","volume":"4","author":"Kircheis","year":"2012","journal-title":"MAbs"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1840196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:20:39Z","timestamp":1784175639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1840196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":26,"alternative-id":["10.3389\/fneur.2026.1840196"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1840196","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1840196"}}